656 filings
Page 3 of 33
F-3
3bf9o74i40p1m8p69j
28 Apr 23
Shelf registration (foreign)
6:09am
6-K
6uzg40y ef
17 Apr 23
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
9:09pm
6-K
vi6bo80 j87l
11 Apr 23
Immutep Announces Changes to the Board
6:06am
6-K
exrtpl
31 Mar 23
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients
5:45pm
6-K
lu0zyq j5h
30 Mar 23
Immutep Announces Expansion of Triple Combination Therapy
5:45pm
6-K
iswt47esfpp54u
14 Mar 23
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
6:05am
6-K
x5qmvzinl7ent
27 Feb 23
Half-Year Financial Report
12:00am
6-K
l6xqp
6 Feb 23
Promising initial efficacy results showing a 72.7% response rate and 90.9% disease control rate reported at SITC 2022
5:04pm
6-K
sl5hwk1nod3
30 Jan 23
Immutep Quarterly Activities Report & Appendix 4C
7:03pm
6-K
ed6vdln8669g1ji9
4 Jan 23
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
6:07am
6-K
31nic27dm6vc6s77j
4 Jan 23
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
6:06am
6-K
zwmqmuka669as 5dmjc
8 Dec 22
Immutep Successfully Achieves Commercial Scale in Manufacturing of
4:44pm
6-K
ijj74
6 Dec 22
Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune Diseases
8:48pm
6-K
j4jhnuaq8ckx1y
29 Nov 22
Current report (foreign)
5:13pm
6-K
1fxipsdhbbzhj19b5g3
14 Nov 22
Immutep receives Australian R&D Tax Incentive
5:55pm
6-K
4zkrw 3vjbmhd0
14 Nov 22
Current report (foreign)
10:04am
6-K
ssh9epr dq
14 Nov 22
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its
10:03am
6-K
xkpob1e8dt5t4l5bv
14 Nov 22
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
10:02am
6-K
qqfaygj1ajaao
9 Nov 22
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha
5:26pm
6-K
8vda3un7
4 Nov 22
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected
5:06pm